Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
Protagenic Therapeutics published preclinical data in Behavioural Pharmacology showing its lead candidate PT00114 reduced physiological and behavioral markers of chronic stress in a rodent model, unlike the comparator CRF₁ receptor antagonist. In the study, PT00114 reduced stress-induced plasma corticosterone by 56.4% and increased time spent in an open field center by 282% versus controls, indicating reduced anxiety-like behavior without changes in locomotion.
Key figures
- Next clinical study year
- 2027
- Time in center increase pct
- 282%
- Corticosterone reduction pct
- 56.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.